Фармакоэкономическое обоснование выбора антикоагулянтной терапии при остром коронарном синдроме
Диссертация
Острый коронарный синдром (ОКС) — форма ишемической болезни, объединяющая острый инфаркт миокарда^ с подъемомсегмента- «БТ» (ОКСсп8Т), острый инфаркт миокарда без подъема сегмента «8Т» и нестабильную стенокардию (ОКСбпБТ). Инфаркт миокардабез подъема сегмента 8 Т отличатся от нестабильной стенокардии только повышением уровня маркеров некроза, миокарда. Эти состояния объединены в единый синдром .в… Читать ещё >
Список литературы
- Авксентьева М.В., Воробьев П. А., Герасимов В. Б., Горохова С. Г., Кобина С. А. Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ). — С. Ньюмедиамед, 2000. с 14−17. 18−30.
- Белоусов Ю.Б. (ред.). Планирование и проведение клинических исследований лекарственных средств. Издательство Общества Клинических Исследователей. М. 2000 г.
- Берестов С.А., Овчинникова О. Е., Баркаган З. С. Экономическая оценка использования гепарина и фраксипарина в отделении патологии беременных. Проблемы стандартизации в здравоохранении. 2000. № 4. С. 22−23.
- Всероссийское научное общество кардиологов. Рекомендации по лечению острого коронарного синдрома без стойкого подъёма сегмента ST на ЭКГ. Кардиология. 2004. № 4 (приложение: 1−28).
- Эрлих А.Д., Грацианский Н. А. Независимый регистр острых коронарных синдромов РЕКОРД. Athero.ru. с 11−18.
- АСС/АНА 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol, 2007- 50:652−726, doi:10.1016/j.jacc.2007.02.028 (Published online 6 August 2007).
- A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med. 1998−228: 1498−1505.
- Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA 2000−283:347−53.
- Ambrose JA, Dangas G. Unstable angina: current concepts of pathogenesis and treatment. Arch Intern Med 2000−160: 25−37.
- Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003−107:2884−8. DOI 10.1161/01.CIR.77 530.53367.E9
- Andersson LO, Barrowcliffe TW, Holmer E, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb Res. 1979−5:531−541.
- Anderson K, Erikson P, Dellborg M. Non-invasive risk stratification within 48 h in hospital admission in patients with unstable coronary disease. Eur Heart J 1997−18:780−8.
- Antman EM. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on. Am Heart J 2003−146:191−3.
- Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000−284:835−42.
- Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxparin for unstable angina/non-Q-wave myocardial infarction: TIMI1 IB-ESSENCE meta-analysis. Circulation 1999−100:1602−8.
- Balen, RM, Marra, CA, Zed, PJ, et al Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999- 16(5 pt 2), 533−542
- Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004−170:1678−86. DOI 10.1503/cmaj.l040498.
- Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985- 39:631- 636.
- Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 1988−543:65−72.
- Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972−287:324 -327.
- Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res. 1973−5:167−179.
- Bazzino O, Diaz R, Tajer C, et al. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. Am Heart J 1999−137:322−31.
- Becker RC, Bovill EG, Seghatchian MJ, Samama MM. Pathobiology of thrombin in acute coronary syndromes. Am Heart J 1998- 136(suppl):S 19−31.
- Becker RC, Bums M, Every N, et al. Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: a nationwide perspective. Arch Intern Med 2001−161:601−7.
- Bell DM. Analysis of number needed to treat and cost of platelet glycoprotein Ilb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. Pharmacotherapy 1999−19:1086−93.
- Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000−21:1406−1432.
- Bergqvist D, Nilsson B, Hedner U, et al. The effects of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res. 1985−38:589 -601.
- Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982−31:104 -113.
- Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000−101:2557−67.
- Boon DM, Michiels JJ, Stibbe J, et al. Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet. 1994−344:1296. Letter. heparin-catalyzed bovine antithrombin/protease reaction. J Biol Chem. 1983−258:1086−1091.
- Bosanquet, N, Fox, KAA Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one-year data. Br J Cardiol 2001−8,36−37
- Bozovich, G, Gurfinkel, E, Barreiro, D, et al Reduction of hospital costs for patients with acute non-Q-wave myocardial infarction or unstable angina treated with enoxaparin compared to standard heparin abstract. Eur Heart J 1999−20,545
- Bratt G, Tornebohm E, Widlund L, et al. Low molecular weight heparin (KABI 2165, FRAGMENT): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. ThrombRes. 1986−42: 613−620.
- Braunwald E. Unstable angina: an etiologic approach to management editorial. Circulation 1998−98:2219 -22.
- Braunwald E. Unstable angina: a classification. Circulation 1989−80: 410−4.
- Braunwald E, Antman EM, Beasely JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction: summary article. Circulation. 2002−106:1893−1900.
- Braunwald E, Califf RM, Cannon CP, et al. Redefining medical treatment in the management of unstable angina. Am J Med 2000−108:41−53.
- Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. 3−1-1994- AHCPR Publication No. 94−0602:1−154.
- Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991−324:370−6.
- Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993- 119:104 -109.
- Cairns, JA, Theroux, P, Lewis, HD, et al (2001) Antithrombotic agents in coronary artery disease. Chest 119,228S-252S
- Calvin JE, Klein LW. Defining risk in unstable angina: current trial design does not tell us who should be treated and with what therapy. Am Heart J 1999−137:199−202.
- Calvin JE, Klein LW, VanderBerg BJ, et al. Risk stratification in unstable angina: prospective validation of the Braunwald classification. JAMA 1995−273:136−41.
- Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE. Validated risk stratification model accurately predicts low risk patients with unstable angina. J Am Coll Cardiol 2000−36:1803−8.
- Cannon CP, McCabe CH, Bentley J. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 abstr.: J Am Coll Cardiol 2001 -37(suppl):334A.
- Choay J, Lormeau JC, Petitou M, et al. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci. 1981−370:644−649.
- Christenson RH, Azzaizy HME. Biochemical markers of the acute coronary syndromes. Clin Chem 1998−44:1855−64.
- Cohen M, Demers C, Lelouer F, et al. One year follow up of the ESSENCE trial (enoxaparin versus heparin in unstable coronary artery disease). J Am Coll Cardiol. 1998−31:79A. Abstract.
- Cohen M, Theroux P, Frey MJ, et al. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation, 2000−102(suppl):II-826.
- Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.1.t J Cardiol 1999- 71:273−81.
- Cohen M, Stinnett SS, Weatherley BD, et al. Predictors of recurrent ischemic events and death, in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000- 139:962−70.
- Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin' pretreatment in patients with unstable angina pectoris. Circulation 2001−103:658 -63. Lancet 1999- 353:429 -38.
- Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997- 336:847 860.
- Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001- 22: 1716−24.
- Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med.1991- 151:333−337.
- Dangas G, Mehran R, Wallenstein S, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997- 29:519−25.
- Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000- 83:361−6.
- Dawes J, Popper DS. Catabolism of low-dose heparin in man. Thromb Res. 1979- 14:845−860.
- DiChiara A, Fresco C, Savonitto S, at al, on behalf of the BLITZ-2 Investigators. Epidemiology non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J 2006- 27: 393:405.
- Diuguid DL. Choosing a Paranteral Anticoagulant Agent. N Engl J Med 2001- 345:18, 1340−1341.
- Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006- 114:774−82.
- Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K, Goldhaber SZ. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 2004- 94:532−5. DOI 10.1016/j.amjcard. 2004.04.075.
- Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989- 663: 114E-120E.
- Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994- 48:583−98.
- Farkouh ME, Smars PA, Reeder GS, et al. A clinical trial of a chest-pain observation unit for patients with unstable angina. N Engl J Med 1998- 339:1882−8.
- Fox KAA, Goodman SG, Klein W on behalf of the GRACE investigators. Management of acute coronary syndromes. Variation in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002- 23: 1177−89.
- Fragmin during Instability in Coronary Artery Disease (FRISC). Thei,
- FRISC Study Group. Low-molecular-weight heparin during instability f in coronary artery disease: Fragmin during instability in Coronary Artery Disease
- FRISC) Study Group. Lancet. 1996- 347:561−568.
- Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes, part I. N Engl J Med. 1992- 326:242−250.
- Fuster V. Mechanisms of arterial thrombosis: foundation for therapy. Am Heart J 1998- 135(suppl):S361−6.
- Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronaiy artery disease. Arch Intern Med 1999- 130:719−23.
- Gibbons RJ, Fuster V, Therapy for Patients with Acute Coronary Syndromes New Opportunities. N Engl J Med 2006,354- 1524−14.
- Glazier RL, Corwell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA. 1976- 236:1365−1367.
- Goldman L, Cook EF, Johnson PA, Brand DA, Rouan GW, Lee TH. Prediction of the need for intensive care in patients who come to emergency departments with acute chest pain. N Engl J Med 1996- 334:1498−504.
- Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000−36:1507−13.
- Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. J Am Coll Cardiol 2000- 36:693−8.
- Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996- 93:870 -8.
- Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995- 91:1929 -35.
- Griffiths E, Dzik WH'. Assays for heparin-induced thrombocytopenia. TransfusMed. 1997- 7:1−11.
- Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight' heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995- 26:313- 8.
- GUSTO IIA Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994- 90:1631−1637.
- GUSTO IIB Investigators, Topol E, Califf R, et" al. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996- 335:775−782.
- Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000- 102:118 -22.
- Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin* T or troponin I. N Engl J Med 1997- 337:1648−53
- Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992- 327:146−50.
- Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1990- 16:12−18.
- Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co- 1992:1−16.
- Harrington R, Becker R, Cannon C, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes. Chest 2008- 133:670S-677S. DOI 10.1378/chest.08−0691.
- Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis 1995- 2:245−9.
- Heeschen C, Hamm CW, Due A, Langenbrink L, White H. Costs and effectivity of treatment with tirofiban in patients with unstable angina- results from the PRISM trial abstr. J Am Coll Cardiol 2000- 35(suppl):393A.
- Hirsh J. Heparin. N Engl J Med 1991−324:1565−74.
- Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 1998- 98:1575−1582.
- Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992- 79:1−17.
- Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004−126:188S-203S.
- Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998- 114-.489S-510S.
- Hirsh J, Weitz JI. New antithrombotic agents. Lancet. 1999- 353: 1431−1436.
- Hochman JS, Wali AU, Barvila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999- 138:313- 8.
- Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994- 24:39−45.
- Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor Xlla and kallikrein by antithrombin. BiochemJ. 1981−193:395−400.
- Holmer E, Soderberg K, Bergqvist D, et al. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986- 16(suppl 2): 1−7.
- Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997- 31:192−203.
- HullRD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in- the initial treatment of proximal-vein thrombosis. N Engl I Med. 1986- 315:1109 -1114.
- Janzon M, Levin L-A, Swahn E. Cost-effectiveness of early invasive treatment in unstable coronary artery disease: a one-year follow-up from the FRISCII invasive trial abstr. J Am Coll Cardiol 2001- 37(suppl):376A.
- Jordan RE, Favreau LV, Braswell EH, et al. Heparin with two-binding sites for antithrombin or platelet factor 4. J Biol Chem. 1982- 257: 400−406.
- Kastrati A., Neumann F.-J., Mehilli J., Byrne R. A., et al., the ISAR-REACT 3 Trial Investigators. Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. N Engl J Med 2008- 359:688−696, Aug 14.
- Katz DA, Griffith JL, Beshansky JR, Selker HP. The’use of empiric clinical' data in the evaluation of practice guidelines for unstable angina. JAMA 1996- 276:1568−74.
- Kaul S, Shah PK. Low molecular weight heparin in’acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin. J Am Coll Cardiol 2000- 35:1699−712.
- Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol. 1980- 17:259−291.
- Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988- 72:925−930.
- Langer A-, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and- association with- coronary anatomy and hospital outcome. J Am Coll Cardiol 1989- 13:1495−502.
- Leape LL, Brennan TA, Laird N, et all The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med-1991- 324:377−84.
- Libby P. Current concepts of the pathogenesis of the acute, coronary syndromes. Circulation 2001- 104:365−72.
- Lindahl U, Backstrom G, Hook M, et al. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA. 1979- 76:3198 -3202.
- Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Effect on mortality by LMW heparin in relation to STT changes and level of troponin T in unstable coronary artery disease: a FRISC II substudy abstr. Circulation 2000- 102(suppl): 11−826.
- Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable angina. Circulation 1996- 93:1651−7.
- Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997- 29:43−8.
- MacMahon S, Collins R, Knight C, et al. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. Circulation. 1988- 78(suppl II):II-98. Abstract.
- Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database of Systematic Reviews 2008. DOI 10.1002/14 651 858.CD002132.
- Mant MJ, O’Brien BD, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet. 1977- 1:1133−1135.
- Mathew T, Menown I, Smith B, et al. Diagnosis and risk stratification of patients with anginal pain and non-diagnostic electrocardiograms. Q J Med 1999- 92:565−71.
- Mathis AS. Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes. Ann Pharmacother 2000- 34:208−27.
- Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome: results from the ESSENCE trial. Circulation 1998- 97:1702−7.
- Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein Ilb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000- 101:366−71.
- Matthai WH Jr, Siegel JE. Heparin-induced thrombocytopenia: diagnostic and therapeutic considerations. J Clin Outcomes Manage 2000- 7:47−53.
- Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J 2008- 156:209−15. DOI 10.1016/j.ahj.2008.03.023
- Miller WL, Reeder GS. Adjunctive therapies in the treatment of acute coronary syndromes. Mayo ClinProc 2001- 76: 391−405.
- Mombelli G, Marchetti O, Haeberli A, Straub PW. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. Am Heart J 1998- 136:1106−13.
- Mukherjee D, Fang J, Kline-Rogers E, Otten R, Eagle KA. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups. Heart 2005- 91:381−2.
- Neri SG, Gensini GF, Poggesi L, et all Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990- 335:615- 8.
- Neri SG, Roveli F, Gensini GF, et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet. 1987- 1: 937−942.
- Newby LK, Storrw AB, Gibler WB, et al. Bedside multimarker testingfor risk stratification in chest pain units: the chest pain evaluation by creatinekinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001−103:1832−7.
- Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998- 56:259−72.
- Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. J Intern Med 1993- 234:293−301.
- O’Brien BJ, Willan A, Blackhouse G, at al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndromes save costs in Canada? Am Heart J 2000- 139:423−9.
- Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and- death in patients with unstable angina. A meta-analysis. JAMA 1996- 276:811−5.51.
- Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. Is this patient having a myocardial infarction? JAMA 1998- 280:1256−63.
- Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998- 338:1498 -505.
- Pope JH, Aufderheide TP, Ruthazer R et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000- 342:1163−70.
- Pozen MW, D’Agostino RB, Mitchell JB et al. The usefulness of a predictive instrument to educe inappropriate admission to the coronary care unit. Ann Intern Med 1980- 92:238−42.
- Pozen MW, D’Agostino RB, Selker HP, Sytkowski PA, Hood WB J. A predictive instrument to improve coronary-care unit admission practices in acute ischemic heart disease: a prospective multicenter clinical trial. N Engl J Med 1984- 310:1273−8.
- Rentrop KP. Thrombin in acute coronary syndromes: revisited and revised. Circulation 2000- 101:1619−26.
- Roberts RR, Zalenski RJ, Mensah EK, et al. Costs of an emergency department-based accelerated diagnostic protocol vs. hospitalization in patients with chest pain: a randomized controlled trial. JAMA 1997- 278:1670−6.
- Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA. 1979- 76:1218 -1222.
- Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D. Age, clinical presentation and outcome of acute coronary syndromes in the Euro Heart Acute Coronary Syndrome Survey. Eur Heart J 2006- 27: 789−95.
- Rusticali G, Bugiardini R. Unstable angina and non-Q-wave myocardial infarction: early risk stratification: role of silent ischemia and coronary morphology. Int J Cardiol 1999- 68(suppl):S43−7.
- Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975- 292:1046−1050.
- Santopinto J, Gurfinkel EP, Torres V, et al. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001- 141:566−72.
- Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999- 281:70 713
- Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005- 142:251−9.
- Seres L, Valle V, Murrugat J, et al. Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. Am J Cardiol 1999- 84:963−9.
- Shapiro SS. Treating Thrombosis in the 21st Century. N Engl J Med 2003,349- 1762−1764−18.
- Solodky A, Behar S, Boyko V, Battler A, Hasdai D. The outcome of coronary artery bypass grafting surgery among patients hospitalized with acute coronary syndrome: The Euro Heart Survey of acute coronary syndrome experience. Cardiology 2005- 103: 44−7.
- Siegbahn A, Diderholm E, Lagerqvist B, et al. Reduced risk ofmyocardial infarction at raised fibrinogen levels by long-term treatment with
- W heparin (dalteparin) in unstable CAD abstr. Circulation 2000- 102 (suppl): 11−589:
- Simoons ML, Bobbink IWG, Boland J at al. A Dose-Finding Study of Fondaparinux in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
- Telford AM, Wilson C. Trial of heparin versus atenolol in. prevention of myocardial infarction- in^ intermediate coronarysyndrome. Lancet 1981- 1:1225−8.
- The RISC Group: Risk of myocardial infarction and death during treatment: with low dose aspirin and intravenous heparin in men with unstable coronary artery disease- Lancet. 1990- 336:827- 830-
- Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute-unstable angina. N Engl J Med 1988- 319:1105−11.
- Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998- 97:1195−206.
- Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992- 327:1*415.
- Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993- 88:2045- 8.
- The SCATI (Studio sulla Calciparina nell’Angina e nella Thrombosi Ventricolare nellTnfarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet. 1989- 2:182−186.
- The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin in unstable angina: results of TIMI 11 A. J Am Coll Cardiol 1997−29:1474−82.
- Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995- 332: 635−41.
- Tosteson ANA, Goldman L, Udvarhelyi IS, Lee TH. Cost-effectiveness of a coronary care unit versus an intermediate care unit for emergency department patients with chest pain. Circulation 1996- 94:143−50.
- Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb. Haemost.1999- 81: 214 -220.
- Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999- 82(suppl):439 -447.
- Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996- 92: 494−497.
- Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998- 79:1−7.
- Warkentin TE, Greinacher A. Clinical picture of heparin-induced thrombocytopenia. In: Heparin-induced Thrombocytopenia. New York, NY: Marcel Redder, 2004:53−106. S81-S90.
- Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996- 101:502−507.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995- 332:1330−5.
- Warkentin TE, Levine MN, Hirsh J, et al. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial. Blood. 1995- 86(suppl l):537a. Abstract.
- Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood. 2000- 96: 1703−1708.
- Weitz JL Low-molecular-weight heparins. N Engl J Med. 1997- 337: 688−698.
- Weitz JI, Bates SM. Beyond heparin and aspirin: new treatments-for unstable angina and"non-Q-wave myocardial infarction. Arch Intern Med 2000- 160:749−58-
- White HD. Optimal treatment of patients with' acute coronary syndromes and non-ST-elevation myocardial1 infarction. Am Heart J 1999- 138(suppl):Sl 05−14.
- White RD, Grande P, Califf L, Palmeri ST, Califf RM, Wagner GS. Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. Am J Cardiol 1985- 55:1478−84.
- Widimsky P. ACS Registries. E-journal of Cardiology Practice. Vol 5 № 40. 27 Aug 200, 1−4.
- Williams DO, Kirby MG, McPherson K, Phear DN. Anticoagulant treatment of unstable angina. Br J Clin Pract 1986−40:114 -6.
- Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J. 1979−97:155−158.
- Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998- 97:251- 6.
- Yeghiazarians Y, Braunstein J B, Askari A, Stone P H. Unstable Angina Pectoris N Engl J Med 2007, 342- 101−111−2.
- Young E, Prins M, Levine MN, et al. Heparin binding to- plasma proteins, an important mechanism for heparin resistance. Thromb Haemost.1992- 67:639−643.
- Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994- 71: 300 -304.
- Yusuf S, Mehta SR., Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators N Engl J Med 2006−354:1464−76.
- Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006−295:1519 -30.
- Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable angina and non-Q-wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999- 33:107−18.
- Zed PJ, Frighetto L, Sunderji R, Marra CA. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective. Ann Pharmacother 1998- 32:536−42.
- Zimmerman J, F omm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999- 99:1671−7.